Answers are grounded in this paper and cite their sources.
Objectives The validation of accurate three-dimensional (3D) models holds significant importance for anti-cancer drug development and screening processes, aiming to minimise the time and resources lost during their development using conventional procedures. Here, we investigated whether bioengineered PEG-Hep hydrogels, a bioengineered breast tumour model, can be used to characterise the responses of immortalised breast cancer cell lines or primary patient-derived breast cancer tumouroids to anti-cancer treatments in 3D. Methods Drug-hydrogel interactions were first assessed using ultraviolet spectroscopy and liquid chromatography-mass spectrometry to determine drug retention and penetration within PEG-Hep hydrogels. Subsequently, we used several different anti-cancer drugs representing first-, second- and third-line treatments across three molecular subtypes (ER/PR+, HER2+ and TNBC) using five breast cancer cell lines. Drug responses were compared between conventional two-dimensional (2D) cultures and 3D PEG-Hep cultures through dose-response and IC50 analyses. Finally, primary breast cancer cells were cultured in PEG-Hep hydrogels and exposed to clinically relevant therapies, including doxorubicin, paclitaxel, and eribulin. Results PEG-Hep hydrogels exhibited distinct drug retention profiles dependent on drug-polymer interactions. Cell lines formed spheroids within PEG-Hep hydrogels, and treatments significantly inhibited spheroid formation and growth while increasing HIF1-α accumulation, indicative of drug-induced cellular stress. Patient-derived tumouroids responded to one or more anti-cancer agents, with doxorubicin demonstrating efficacy across all samples. Conclusions This study has demonstrated PEG-Hep hydrogels to be a versatile and robust 3D platform for elucidating drug-cell interactions within the context of breast cancer. Moreover, this study contributes towards the implementation of semi-synthetic hydrogels for the advancement of personalised medicine.
No takes yet. Share an insight, caveat, or question.
Clegg et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: